# A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

> **NCT06949761** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 240 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** QLC1101+QL1203
- **DRUG:** QLC1101+QL2107
- **DRUG:** QLC1101+QL1706
- **DRUG:** QLC1101+docetaxel

## Key facts

- **NCT ID:** NCT06949761
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06
- **Primary completion:** 2026-09
- **Final completion:** 2027-06
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06949761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06949761, "A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06949761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*